ArticleJournal of medical economics2019
Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Registry-linked trialAbstract read
In one paragraph
Article in Journal of medical economics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05700344 (Multicentric, Observational Study to Evaluate Real World Data of Avelumab in First Line Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, a SOGUG Study), which is not on this map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicentric, Observational Study to Evaluate Real World Data of Avelumab in First Line Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, a SOGUG Study
Who cites it
22 citing papers in PubMed.
- Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Astellas article: UK multidisciplinary recommendations on use of combination first-line enfortumab vedotin▼ and pembrolizumab in advanced urothelial carcinoma.The oncologist · 2025Article
- Impact of treatment patterns and sequencing on clinical and economic outcomes in patients with metastatic urothelial cancer: IMPACT UC II study.The oncologist · 2025Article
- Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.The oncologist · 2025Article
- Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.Current oncology (Toronto, Ont.) · 2025Article
- Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network.ESMO real world data and digital oncology · 2025Article
- Observational
- Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.JAMA network open · 2024Article
- Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Systemic anticancer therapy for urothelial carcinoma: UK oncologists' perspective.British journal of cancer · 2024Review
- Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.The oncologist · 2024Article
- Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis.Future oncology (London, England) · 2024Article
- Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.Therapeutic advances in medical oncology · 2024Article
- Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.Scientific reports · 2023Article
- Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).The oncologist · 2023Article
- Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature.PharmacoEconomics · 2023Review
- Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.Asia-Pacific journal of clinical oncology · 2022Review
- Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Abdalla Alya Real-World Evidence and Data Analytics, Pharmerit International , Bethesda , MD , USA.
Courtney Johnsona Real-World Evidence and Data Analytics, Pharmerit International , Bethesda , MD , USA.
Shuo Yangb US Health Economics Outcomes Research, Bristol-Myers Squibb , Princeton , NJ , USA.
Marc F Bottemana Real-World Evidence and Data Analytics, Pharmerit International , Bethesda , MD , USA.ORCID http://orcid.org/0000-0003-2808-7163
Sumati Raob US Health Economics Outcomes Research, Bristol-Myers Squibb , Princeton , NJ , USA.
Arif Hussainc Hormone Responsive Cancers Program, University of Maryland Greenebaum Comprehensive Cancer Center and Baltimore VA Medical Center , Baltimore , MD , USA.
Funding
Optimization of Multi-Modal Therapies in Pre-clinical models of Prostate CancerI01BX000545 · VA · BALTIMORE VA MEDICAL CENTER · PI HUSSAIN, ARIF · 2009 to 2021
–BLRD VA I01 BX000545
Abstract
PubMed holds no abstract for this paper.
Indexed as
Health Care CostsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellCohort StudiesFemaleHealth ResourcesHumansKaplan-Meier EstimateMaleMedicareNeoplasm InvasivenessNeoplasm MetastasisNeoplasm StagingProportional Hazards ModelsA10E37economic burdenhealthcare resource useline of therapyMetastatic urothelial carcinomaSEER-Medicare
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05700344ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.